ACCORD Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACCORD, and when can generic versions of ACCORD drugs launch?
ACCORD has one hundred and fifty-five approved drugs.
There are four US patents protecting ACCORD drugs. There are three tentative approvals on ACCORD drugs.
There are thirty-five patent family members on ACCORD drugs in eighteen countries and three hundred and eighty-seven supplementary protection certificates in eighteen countries.
Summary for ACCORD
| International Patents: | 35 |
| US Patents: | 4 |
| Tradenames: | 132 |
| Ingredients: | 129 |
| NDAs: | 155 |
| Patent Litigation for ACCORD: | See patent lawsuits for ACCORD |
| PTAB Cases with ACCORD as petitioner: | See PTAB cases with ACCORD as petitioner |
Drugs and US Patents for ACCORD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | RAMIPRIL | ramipril | CAPSULE;ORAL | 202392-004 | Apr 15, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Accord Hlthcare | PEMETREXED DISODIUM | pemetrexed disodium | SOLUTION;INTRAVENOUS | 214408-001 | Jul 19, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Accord Hlthcare | PRASUGREL | prasugrel hydrochloride | TABLET;ORAL | 205987-001 | Feb 2, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ACCORD drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
International Patents for ACCORD Drugs
Supplementary Protection Certificates for ACCORD Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0281713 | 96C0031 | Belgium | ⤷ Sign Up | PRODUCT NAME: MYCOPHENOLATE MOFETIL; NAT. REGISTRATION NO/DATE: EU/1/96/005/001 19960214; FIRST REGISTRATION: CH 53337 19951103 |
| 1003503 | C01003503/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: AMLODIPIN + ATORVASTATIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57633 05.07.2006 |
| 1427415 | 122011100050 | Germany | ⤷ Sign Up | PRODUCT NAME: APIXABAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/11/691/001-005 20110518 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
